Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649229 · ClinicalTrials.gov registry record · Phase 4
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
A Phase 4 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT04649229: Completed Phase 4 study, sponsored by Yale University.
NCT04649229 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04649229, a Phase 4 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
Primary Outcome
Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days
Interventions
- DRUG Placebo
- DRUG Iohexol
- DRUG Aprepitant
- DRUG LCZ 696
- DRUG Para-aminohippurate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 4 |
What the finished NCT04649229 record still lists
NCT04649229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04649229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04649229 about?
NCT04649229 is a clinical study titled "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3". This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
What is the current status of trial NCT04649229?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2021-05-27. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT04649229?
The interventions under investigation include: Placebo (DRUG), Iohexol (DRUG), Aprepitant (DRUG), LCZ 696 (DRUG), Para-aminohippurate (DRUG).
Who is sponsoring clinical trial NCT04649229?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04649229's enrollment target sits among peer trials
46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI